Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection impacted morbidity and mortality during the pandemic of 2020–2021. A number of anti-COVID-19 vaccines have been developed with an unprecedented speed. While these vaccines have good efficacy and are safe, the experience with their use is limited and hence the knowledge of rare side effects. Identifying rare… Continue reading Hepatitis #C Virus Reactivation Following #COVID-19 Vaccination – A Case Report
Category: Hepatology
ADAMTSL2 protein and a soluble biomarker signature identify significant and advanced #fibrosis in adults with #NAFLD
Using an aptamer-based profiling platform we identified an individual and panel of circulating proteins that non-invasively identify significant fibrosis at-risk NASH in 316 adults with NAFLD.•An 8-protein panel can distinguish NAFL/NASH fibrosis stage 0-1 from fibrosis stage 2-4 with an AUROC 0.87- 0.89.•The ADAMTSL2 protein alone can distinguish NAFL/NASH fibrosis stage 0-1 from fibrosis stage… Continue reading ADAMTSL2 protein and a soluble biomarker signature identify significant and advanced #fibrosis in adults with #NAFLD
Metabolic associated fatty #liver disease is the risk factor for chronic #kidney disease
Background & AimsTo clarify the relationship between metabolic dysfunction-associated fatty liver disease (MAFLD) and chronic kidney disease (CKD). MethodsThe participants were divided into four groups by the presence or absence of fatty liver disease (FLD) and metabolic dysfunction (MD). MAFLD was defined as having both FLD and MD, whereas CKD was defined as estimated glomerular… Continue reading Metabolic associated fatty #liver disease is the risk factor for chronic #kidney disease
Synthesis of human #amyloid restricted to #liver results in an #Alzheimer disease–like neurodegenerative phenotype
Several lines of study suggest that peripheral metabolism of amyloid beta (Aß) is associated with risk for Alzheimer disease (AD). In blood, greater than 90% of Aß is complexed as an apolipoprotein, raising the possibility of a lipoprotein-mediated axis for AD risk. In this study, we report that genetic modification of C57BL/6J mice engineered to… Continue reading Synthesis of human #amyloid restricted to #liver results in an #Alzheimer disease–like neurodegenerative phenotype
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic #fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study
AMP kinase (AMPK) is an energy sensor implicated in regulation of lipid metabolism, inflammation, and insulin sensitivity. We aimed to assess efficacy and safety of PXL770, a novel direct AMPK activator, in patients with non-alcoholic fatty liver disease (NAFLD). MethodsSTAMP-NAFLD, a randomised, double-blind, placebo-controlled phase 2a study, was done across 15 US clinical sites. Patients… Continue reading Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic #fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study
Role and Mechanism of Gut #Microbiota in Human #Disease
The human gut microbiome is a huge microbial community that plays an irreplaceable role in human life. With the further development of research, the influence of intestinal flora on human diseases has been gradually excavated. Gut microbiota (GM) dysbiosis has adverse health effects on the human body that will lead to a variety of chronic… Continue reading Role and Mechanism of Gut #Microbiota in Human #Disease
#Elastography is unable to exclude #cirrhosis after sustained virological response in #HCV-infected patients with advanced chronic liver disease
Liver fibrosis and transient elastography (TE) correlation in hepatitis C virus (HCV)-infected patients with compensated advanced chronic liver disease (cACLD) after sustained virological response (SVR) is unknown. AimsTo evaluate TE accuracy at identifying cirrhosis 3 years after HCV-eradication. MethodsProspective, multi-centric study including HCV-cACLD patients before direct-acting antivirals (DAA). Diagnostic accuracy of TE (area under ROC,… Continue reading #Elastography is unable to exclude #cirrhosis after sustained virological response in #HCV-infected patients with advanced chronic liver disease
#Cysteamine Decreases Low‐Density Lipoprotein Oxidation, Causes Regression of #Atherosclerosis, and Improves #Liver and Muscle Function in Low‐Density Lipoprotein Receptor–Deficient Mice
We have shown previously that low‐density lipoprotein (LDL) can be oxidized in the lysosomes of macrophages, that this oxidation can be inhibited by cysteamine, an antioxidant that accumulates in lysosomes, and that this drug decreases atherosclerosis in LDL receptor–deficient mice fed a high‐fat diet. We have now performed a regression study with cysteamine, which is… Continue reading #Cysteamine Decreases Low‐Density Lipoprotein Oxidation, Causes Regression of #Atherosclerosis, and Improves #Liver and Muscle Function in Low‐Density Lipoprotein Receptor–Deficient Mice
#Pradefovir Treatment in Patients with Chronic Hepatitis #B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial
Pradefovir is a liver-targeted prodrug of adefovir, a nucleotide analog with antiviral activity against hepatitis B virus (HBV) DNA polymerase. This phase 2 study compared the efficacy and safety of oral pradefovir (30mg, 45mg, 60mg, and 75mg) versus tenofovir disoproxil fumarate (TDF; 300mg) and aimed to identify the most appropriate dose of pradefovir for the… Continue reading #Pradefovir Treatment in Patients with Chronic Hepatitis #B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial
2 Medical News 